Zoltan Luttenberger’s Post

Epic day for Exact! As CRC evolves let’s focus on the BLUE-C findings when comparing Head-Head with FIT. Every endpoint met and even increased separation in terms of sensitivity and specificity… non-invasive folks 45+, make this a priority.

At PYC we develop precision therapeutics with disease-modifying potential, with patient outcomes at the forefront of our minds. Drugs that act to rescue the disease phenotype, rather than just manage symptoms, have the potential to revolutionise healthcare and patient prognosis. VP-001 is designed to address the underlying cause of Retinitis Pigmentosa type 11, a severe blinding disease with childhood onset. It is compelling to see meaningful improvements in vision in patients treated with VP-001 in the ongoing Phase 1/2 studies. VP-001 is the first drug candidate to have entered clinical trials for this major unmet patient need.

The mechanisms of itch are more complex than we often realize, and there remains a significant unmet need for precise treatment of this symptom. In next week's seminar, we are excited to invite Dr. Hao-Jui Weng, an internationally recognized expert, to uncover the basic science and clinical translation of itch.

🎉 A New Special Issue "Emergency Medicine: Clinical Advances and Challenges in Diagnosis and Treatment, 2nd Edition" is open for submission! 👨🔬 Guest Editor: Prof. Dr. Ovidiu Alexandru Mederle ⏳ Submission deadline: 25 May 2025 https://lnkd.in/dgK6NCfj 💥 The first volume published 14 articles and was a great success! https://lnkd.in/dSx8K3pb 👏 Welcome to visit for more details and submit your paper to this Special Issue! #PersonalizedMedicine #EmergencyMedicine

🔬Explore the clinical microbiome with #mSystems journal—from technology to application! Join our next free mSystems Thinking Series webinar on May 6 at 10 p.m. EDT (May 7, 10:00 a.m. CST China), featuring mSystems Editors Shi Huang, Ph.D., Hongwei Zhou, Ph.D. and moderator Jian Xu, Ph.D. This discussion promises to offer valuable insights and foster knowledge exchange on recent advancements in analyzing microbiota in host-rich clinical specimens and investigating host and microbiota relations in complex chronic diseases. Don't miss out on this opportunity to expand your knowledge and join this interactive conversation! ➡️Reserve your spot now: https://brnw.ch/21wJagI #ClinicalMicrobiome #MicrobiomeResearch #ScienceWebinar

Join us at #UEGWeek where Dr. Vipul Jairath, Principal Investigator for the VERDICT study, will present data on target achievement in patients with moderate to severe ulcerative colitis participating in the VERDICT study, a trial focused on evaluating different algorithms of achieving treatment target in ulcerative colitis. Stop by booth #57 to learn more about our innovative research! #Alimentiv #IBD #ClinicalResearch

Listen from #CEPCAL President Dr. Claudia Gonzaga-Jauregui chatting with Kira Dineen, MS, LCGC, CG(ASCP)CM as part of the PhenoTips #SpeakerSeries about #RareDiseases, the importance of molecular diagnosis to obtain better care and access to potential therapies, and the need to make genomic technologies affordable and accessible in #LatinAmerica for equitable healthcare.

Clinical focus: Deep margin elevation. Restoring subgingival margins with deep margin elevation (DME) addresses many clinical challenges. Dr Anu Polster (DIME Commitee) presents an overview of a recent and wide-ranging review on the subject. https://lnkd.in/gY_K5Ppk

Great lecture on Lithium by Dr. Meyer!

Catch the latest updates in #HAE from #EAACI2024